DC Funds, LP

In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 14, 2026), DC Funds, LP reported 3 stock positions worth $1.5 million. Its top holding was Tscan Therapeutics (TCRX) at 42.4% of the portfolio, followed by Werewolf Therapeutics (HOWL, 33.0%) and Barinthus Biotherapeutics PL (BRNS, 24.6%). Its holdings were unchanged from Q4 2025.

Most Recent 13F
Q2 2026
Location
MCLEAN, VA
CIK
0001869028
Portfolio Value
$1.5M (Q1 2026)
SEC Filing
0001398344-26-009112 ↗ filed May 14, 2026

Holdings Value

0$5.0M$10.0M$15.0M Q1 2024: $10.3M Q1 2024 Q2 2024: $6.0M Q2 2024 Q3 2024: $5.2M Q3 2024 Q4 2024: $3.6M Q4 2024 Q1 2025: $2.1M Q1 2025 Q2 2025: $2.2M Q2 2025 Q3 2025: $3.1M Q3 2025 Q4 2025: $1.5M Q4 2025 Q1 2026: $1.5M $1.5M Q1 2026 Q2 2026: $1.3M Q2 2026

Holdings 3 stocks · $1.5M
TCRX Tscan Therapeutics Inc. 42.40% 630,000 $630K No change
HOWL Werewolf Therapeutics Inc. 33.01% 589,102 $490K No change
BRNS Barinthus Biotherapeutics PL 24.59% 642,204 $365K No change

Portfolio Sells Q4 2025 → Q1 2026
None this quarter.

Portfolio Buys Q4 2025 → Q1 2026
None this quarter.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 3$1.3MTCRX, BRNS, HOWL
Q1 2026 3$1.5MTCRX, HOWL, BRNS
Q4 2025 3$1.5MTCRX, BRNS, HOWL
Q3 2025 3$3.1MHOWL, TCRX, BRNS
Q2 2025 3$2.2MTCRX, HOWL, BRNS
Q1 2025 3$2.1MTCRX, BRNS, HOWL
Q4 2024 3$3.6MTCRX, HOWL, BRNS
Q3 2024 3$5.2MTCRX, HOWL, BRNS
Q2 2024 3$6.0MTCRX, HOWL, BRNS
Q1 2024 3$10.3MTCRX, HOWL, BRNS